OLR1 encodes the oxidized low-density lipoprotein receptor 1 (LOX-1), a membrane receptor that primarily functions in lipoprotein metabolism and atherosclerotic processes 1. The protein facilitates cellular uptake of oxidized LDL, contributing to foam cell formation in macrophages during atherosclerosis 1. LOX-1 expression is regulated by ubiquitination, specifically through TRIM31-mediated K48-linked ubiquitination at lysine 12, which promotes its proteasomal degradation 1. Genetic variants in OLR1, particularly rs11053646 and rs3736235, are significantly associated with increased risk of coronary artery disease and ischemic stroke 23. In diabetic kidney disease, OLR1 mediates ox-LDL deposition in podocytes through IGF-1R/RAC1 signaling, contributing to renal injury 4. Beyond cardiovascular disease, OLR1 demonstrates oncogenic properties, being highly expressed in various cancers including head and neck squamous cell carcinoma and gastric cancer, where it correlates with poor prognosis, immune suppression, and enhanced tumor cell invasion 567. The receptor is specifically enriched in tumor-associated macrophages, contributing to immunosuppressive tumor microenvironments 6. OLR1 variants are also associated with polycystic ovary syndrome and atherosclerotic risk factors 8.